Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.

Vaccines (Basel) · 2023 · PMC10145688 · PMID 37112731

Europe PMC DOI

hedged sentence

0.2609

closest p · 5.2× alpha

0.2609

boldest claim

The sentences

a small trendp = 0.2609not close (p > 0.1)

After 5 months after the last vaccination, a small trend in favor of the control group was shown ( p = 0.2609).

also in 138 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.